S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)

MannKind - MNKD Stock Forecast, Price & News

$4.68
+0.25 (+5.64%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.40
$4.70
50-Day Range
$2.99
$4.51
52-Week Range
$2.49
$4.86
Volume
5.57 million shs
Average Volume
4.35 million shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

MannKind MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
28.5% Upside
$6.00 Price Target
Short Interest
Bearish
13.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

782nd out of 1,043 stocks

Pharmaceutical Preparations Industry

377th out of 510 stocks

MNKD stock logo

About MannKind (NASDAQ:MNKD) Stock

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! pixel
MannKind Third Quarter 2022 Earnings: Beats Expectations
MannKind Q3 2022 Earnings Preview
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! pixel
Mannkind Corp
MannKind Corporation
Interesting MNKD Call Options For October 28th
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
See More Headlines
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Company Calendar

Last Earnings
11/08/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
348
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+28.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-80,930,000.00
Net Margins
-127.93%
Pretax Margin
-127.93%

Debt

Sales & Book Value

Annual Sales
$75.44 million
Book Value
($0.90) per share

Miscellaneous

Free Float
257,142,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.68

Social Links


Key Executives

  • Dr. Michael E. Castagna Pharm.D. (Age 45)
    CEO & Director
    Comp: $1.12M
  • Mr. Steven B. BinderMr. Steven B. Binder (Age 59)
    Chief Financial Officer
    Comp: $772.05k
  • Mr. Joseph Kocinsky M.B.A. (Age 58)
    M.S., Chief Technology Officer
    Comp: $608.75k
  • Dr. David B. ThomsonDr. David B. Thomson (Age 55)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $772.9k
  • Dr. Stuart A. Tross Ph.D. (Age 55)
    Chief People & Workplace Officer
    Comp: $652.85k
  • Mr. Thomas Hofmann M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Rosabel Realica Alinaya (Age 61)
    VP of Investor Relations & Treasury
  • Mr. John F. Bedard (Age 72)
    Sr. VP of Worldwide Regulatory Affairs
  • Mr. James Patrick McCauley Jr. (Age 56)
    J.D., M.B.A., Chief Commercial Officer
  • Mr. Alejandro Galindo M.B.A.Mr. Alejandro Galindo M.B.A. (Age 50)
    M.S., Exec. VP of Endocrine Bus. Unit













MNKD Stock - Frequently Asked Questions

Should I buy or sell MannKind stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings
or view top-rated stocks.

What is MannKind's stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for MNKD
or view top-rated stocks among Wall Street analysts.

How have MNKD shares performed in 2022?

MannKind's stock was trading at $4.37 at the beginning of the year. Since then, MNKD shares have increased by 7.1% and is now trading at $4.68.
View the best growth stocks for 2022 here
.

When is MannKind's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MNKD earnings forecast
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company had revenue of $32.83 million for the quarter, compared to analysts' expectations of $25 million. The firm's quarterly revenue was up 47.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.04) earnings per share.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (7.92%), BlackRock Inc. (7.70%), Vanguard Group Inc. (4.98%), Emerald Advisers LLC (1.49%), Polar Asset Management Partners Inc. (0.69%) and Emerald Mutual Fund Advisers Trust (0.70%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends
.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.68.

How much money does MannKind make?

MannKind (NASDAQ:MNKD) has a market capitalization of $1.23 billion and generates $75.44 million in revenue each year. The biopharmaceutical company earns $-80,930,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does MannKind have?

The company employs 348 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 11/30/2022 by MarketBeat.com Staff